Portugal - Portugiesisch - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

tad pharma gmbh - atorvastatina - comprimido revestido por película - 40 mg - atorvastatina cálcica 41.44 mg - atorvastatin - genérico - duração do tratamento: longa duração

Portugal - Portugiesisch - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

tad pharma gmbh - atorvastatina - comprimido revestido por película - 40 mg - atorvastatina cálcica 41.44 mg - atorvastatin - genérico - duração do tratamento: longa duração

Portugal - Portugiesisch - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

tad pharma gmbh - atorvastatina - comprimido revestido por película - 40 mg - atorvastatina cálcica 41.44 mg - atorvastatin - genérico - duração do tratamento: longa duração

Brasilien - Portugiesisch - ANVISA (Agência Nacional de Vigilância Sanitária)

produtos roche quÍmicos e farmacÊuticos s.a. - atezolizumabe - antineoplasico

Europäische Union - Portugiesisch - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Europäische Union - Portugiesisch - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, células escamosas - agentes antineoplásicos - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Brasilien - Portugiesisch - ANVISA (Agência Nacional de Vigilância Sanitária)

merck sharp & dohme farmaceutica ltda. - pembrolizumabe - outros antineoplasicos

Europäische Union - Portugiesisch - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Brasilien - Portugiesisch - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - durvalumabe -

Portugal - Portugiesisch - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

kowa pharmaceutical europe gmbh - pitavastatina - comprimido revestido por película - 1 mg - pitavastatina cálcica 1.045 mg - pitavastatin - n/a - duração do tratamento: longa duração